Alcobra

Alcobra is an Israeli biotechnology company founded in 2008, with headquarters in Tel Aviv. It focuses on developing medications for central nervous system disorders. The company's primary investigational product, ADAIR, is an abuse deterrent formulation of amphetamine immediate release for ADHD. Clinical trials for ADAIR are scheduled to commence in 2017, and pending successful results, Alcobra aims to attain regulatory approval, including from the FDA, by the end of 2018. Alcobra is also working on Metadoxine Extended Release (MDX) for ADHD and Fragile X Syndrome. Notably, both the FDA and EMA have granted Orphan Drug status for MDX, with the FDA designating it as a Fast Track treatment for Fragile X Syndrome. The company has already completed a Phase II clinical trial of MDX for treating adolescents and adults with Fragile X Syndrome. In 2013, Alcobra went public on the NASDAQ Global Market, trading under the symbol ADHD. The company received a post-IPO equity investment of ILS28.50M on 01 March 2014 from Cybele Holdings. Apart from its Tel Aviv headquarters, Alcobra operates a U.S. office in Conshohocken, Pennsylvania, just outside of Philadelphia.